ASSESSMENT OF SLEEP DISORDERS BEFORE AND AFTER ITRACONAZOLE TREATMENT IN SEBORRHEIC DERMATITIS

Objectives: To assess the prevalence of sleep disorders before and after itraconazole treatment in patients with seborrheic dermatitis. Research object and Method: This cross-sectional study included 45 patients diagnosed with seborrheic dermatitis who sought treatment at Can Tho Dermatology Hospital between June 2024 and November 2024. Sleep disturbances were evaluated using the Pittsburgh Sleep Quality Index (PSQI) before and after treatment. The effectiveness of itraconazole was assessed based on symptom severity (erythema, scaling, itching, and burning), scored on a 0–3 scale (none–severe) over six weeks. Results: Before treatment, 28.9% of patients experienced sleep disorders, with prevalence rates of 21.6% in those with moderate SD and 62.5% in those with severe SD. Following itraconazole treatment, the prevalence of sleep disorders significantly decreased to 6.7% (p < 0.001). Treatment outcomes improved over time, with 51.1%, 84.5%, and 95.6% of patients achieving good or excellent results at weeks 2, 4, and 6, respectively. Patients with moderate SD showed better treatment responses compared to those with severe SD. No adverse effects related to itraconazole were reported during the six-week follow-up. Conclusion: Sleep disturbances in seborrheic dermatitis were correlated with disease severity. After itraconazole treatment, patients experienced significant improvements in sleep quality, as indicated by lower PSQI scores. Patients with moderate SD responded more favorably to treatment than those with severe SD. These findings suggest that itraconazole is a safe and effective treatment option for managing both moderate and severe seborrheic dermatitis while also improving sleep quality.